Genomma Lab Internacional SAB de CV
BMV:LABB
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
17.04
28.88
|
| Price Target |
|
We'll email you a reminder when the closing price reaches MXN.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Operating Margin
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
Peer Comparison
| Country | Company | Market Cap |
Operating Margin |
||
|---|---|---|---|---|---|
| MX |
|
Genomma Lab Internacional SAB de CV
BMV:LABB
|
16.8B MXN |
Loading...
|
|
| US |
|
Eli Lilly and Co
NYSE:LLY
|
1T USD |
Loading...
|
|
| US |
|
Johnson & Johnson
NYSE:JNJ
|
530.8B USD |
Loading...
|
|
| CH |
|
Roche Holding AG
SIX:ROG
|
281.3B CHF |
Loading...
|
|
| UK |
|
AstraZeneca PLC
LSE:AZN
|
213.4B GBP |
Loading...
|
|
| CH |
|
Novartis AG
SIX:NOVN
|
223B CHF |
Loading...
|
|
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.8T DKK |
Loading...
|
|
| US |
|
Merck & Co Inc
NYSE:MRK
|
267.6B USD |
Loading...
|
|
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
218B USD |
Loading...
|
|
| US |
|
Pfizer Inc
NYSE:PFE
|
147.1B USD |
Loading...
|
|
| FR |
|
Sanofi SA
PAR:SAN
|
96.5B EUR |
Loading...
|
Market Distribution
| Min | -411.5% |
| 30th Percentile | 5.1% |
| Median | 11.3% |
| 70th Percentile | 21.5% |
| Max | 838% |
Other Profitability Ratios
Genomma Lab Internacional SAB de CV
Glance View
Nestled amid the dynamic landscape of the Mexican pharmaceutical and personal care market, Genomma Lab Internacional SAB de CV has carved a distinct niche for itself since its inception in 1996. The company, recognized for its innovative approach to marketing and product distribution, operates with a dual business model that focuses both on over-the-counter (OTC) medications and a slew of personal care products. This strategic diversification has enabled Genomma Lab to tap into a broad array of consumer needs, expanding its reach beyond the confines of Mexico to a wide array of markets across the Latin American region and beyond. By leveraging a robust distribution network, which includes traditional retailers and modern trade channels, Genomma ensures that its products – from headache remedies to skincare solutions – are easily accessible to consumers, thereby driving consistent revenue growth. Central to Genomma Lab's success is its ability to blend strategic marketing prowess with an agile supply chain. The company's marketing campaigns are meticulously crafted, often highlighting the efficacy and trustworthiness of its products, which resonates well with a cost-sensitive yet quality-oriented consumer base. Furthermore, Genomma Lab thrives on an innovative product pipeline that sees continual introductions and adaptations in response to changing market demands. This commitment to innovation is complemented by cost efficiency in its operations, allowing the company to maintain competitive pricing. With an entrenched brand presence and a solid track record of adaptability, Genomma Lab continues to bolster its market position, focusing on both organic growth and strategic alliances to propel its evolution in the global marketplace.
See Also
Operating Margin is calculated by dividing the Operating Income by the Revenue.
The current Operating Margin for Genomma Lab Internacional SAB de CV is 21.5%, which is above its 3-year median of 20.3%.
Over the last 3 years, Genomma Lab Internacional SAB de CV’s Operating Margin has increased from 19.7% to 21.5%. During this period, it reached a low of 19.3% on Mar 31, 2023 and a high of 21.6% on Jun 30, 2025.